According to a report from the Indian Medical Economics News, Dilip Surana, general manager of Microlabs, a leading export-oriented pharmaceutical company in India, pointed that the Indian pharmaceutical industry now has an excessive dependence on Chinese APIs.
来自《印度医药经济信息》的报道称，印度主要出口型制药公司麦克罗( Micro labs)总经理迪利普·苏拉纳( Dilip Surana)在接受媒体采访时指出，印度制药业对中国的原料药依然有巨大的依赖。
Dilip Surana said: " Since last year (2018), due to the increased supervision of China's environmental protection, the prices of some APIs and intermediates have skyrocketed, followed by frequent supply shortages. It has made huge influence in the market, not only in China but also in India. How to avoid the dilemma of the soaring price of APIs? Many Indian pharmaceutical companies, including Micro labs, have begun to find solutions.”
Picture from in-Pharma Technologist
Indian pharmaceutical companies seek the "largest common denominator" of china-India cooperation
With further segmentation in the world pharmaceutical industry, the strategy to collect both upstream and downstream industry chain of pharmaceutical companies is valuable, but the cost is often too large to take with. The future approach is to establish a mutually beneficial and strategic cooperation supply chain with varied stakeholders.
China and India, as the two largest producers and exporters of APIs in the world, have leading technologies and products respectively.
For example, China has strong market competitiveness in bulk fermentation, raw materials and chemical intermediates, while India has a comparative advantage in the production of high-efficiency chemical raw materials for some European and American generic drugs. It is vital for both parties to maintain a rational competitive relationship.
Picture from: Business Line
Driven by the strict national regulatory policies such as quality, environmental protection and safety, the industrial transformation and upgrading in China's API market has accelerated, and the company in market has improved its product quality and efficiency. As a result, the industry's competitive strength has rapidly increased.
At the same time, as an industry with an outward-looking competitive advantage, the internationalization strategy of APIs should be more stable in the future. Specifically, while abandoning the phenomenon of irregular competition in excessively low-priced exports, India and must adhere to the principle of mutual benefit for trading, focus on the fairness of transactions, follow the competition rules of complementary advantages to ensure market health.
It is imperative to strengthen international cooperation in the production of APIs, especially to find the largest common denominator in the cooperation of APIs in China and India, and to maximize the mutual promotion. This requires serving customers with a more rational attitude, developing a community to sharing market interests, and promoting sustainable cooperation upstream and downstream
The 83rd API China
As the leading exhibition in Chinese pharmaceutical industry, API China converges all related parties in China for policy & regulation interpretation, prictical experience education, product showing and market information press release. During more than 40 years' development, now it also bocomes a celebration for both Chinese pharamceutical enterprises and international ones. With its great influence in the industry, API China has been recognized as the one platform for supplier sourcing and information exchanging.
API China作为中国制药行业的风向标，是中国制药行业各方汇聚一堂，研习最新政策法规，分享国内外企业成功经验，学习中国制药行业最新产品动态，并了解中国制药市场行业信息的极佳平台。经过41年的不断发展，API China现已成为国内外制药行业在中国不可错过的盛会。凭借其出色的行业服务水平与信息交换能力，API China成为了制药企业在中国寻源并展开商务合作的圣地。尤其是在亚洲，更吸引了众多来自印度、韩国、日本、东南亚的制药企业前来参观。